# C_2004177EN.01000301.xml

| 9.7.2004 | EN | Official Journal of the European Union | C 177/3 |
| --- | --- | --- | --- |

9.7.2004

EN

Official Journal of the European Union

C 177/3

---

Prior notification of a concentration

(Case No COMP/M.3497 — Pfizer / Campto)

Candidate case for simplified procedure

(2004/C 177/03)

(Text with EEA relevance)

| 1. | On 25 June 2004, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertakings Pfizer Inc. (‘Pfizer’, United-States) acquires within the meaning of Article 3(1)(b) of the Council Regulation control of the whole of Aventis Campto Business (‘ACB’ France/Germany), controlled by Sanofi-Aventis S.A. (‘Sanofi-Aventis’, France), by way of purchase of assets. |
| --- | --- |

1.

On 25 June 2004, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertakings Pfizer Inc. (‘Pfizer’, United-States) acquires within the meaning of Article 3(1)(b) of the Council Regulation control of the whole of Aventis Campto Business (‘ACB’ France/Germany), controlled by Sanofi-Aventis S.A. (‘Sanofi-Aventis’, France), by way of purchase of assets.

1

| 2. | The business activities of the undertakings concerned are:






  — | for undertaking Pfizer: a research-based, pharmaceutical company, which discovers, develops, manufactures, and markets prescription medicines for humans and animals, and consumer healthcare products, |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

for undertaking Pfizer: a research-based, pharmaceutical company, which discovers, develops, manufactures, and markets prescription medicines for humans and animals, and consumer healthcare products,

| — | for undertaking ACB: produces and sells Campto, a treatment for colorectal cancer in Europe, Africa and Asia, under a license from Yakult Honsha Co. Limited, |
| --- | --- |

—

for undertaking ACB: produces and sells Campto, a treatment for colorectal cancer in Europe, Africa and Asia, under a license from Yakult Honsha Co. Limited,

| — | for undertaking Sanofi-Aventis: pharmaceutical company, which discovers, develops, manufactures, and markets human pharmaceuticals, vaccines, animal health and chemicals products. |
| --- | --- |

—

for undertaking Sanofi-Aventis: pharmaceutical company, which discovers, develops, manufactures, and markets human pharmaceuticals, vaccines, animal health and chemicals products.

| 3. | On preliminary examination, the Commission finds that the notified concentration could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EEC) No 4064/89 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified concentration could fall within the scope of Regulation (EC) No 139/2004. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EEC) No 4064/89 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

2

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (fax no. +32/2/2964301 or 2967244) or by post, under reference number COMP/M.3497 — Pfizer/Campto, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition, |
| Merger Registry |
| J-70 |
| B-1049 Bruxelles/Brussel. |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (fax no. +32/2/2964301 or 2967244) or by post, under reference number COMP/M.3497 — Pfizer/Campto, to the following address:

European Commission

Directorate-General for Competition,

Merger Registry

J-70

B-1049 Bruxelles/Brussel.

---

(1)  OJ L 24, 29.1.2004, p. 1.

1

(2)  OJ C 217, 29.7.2000, p. 32; Council Regulation (EEC) No 4064/89 has been replaced by Council Regulation (EC) No 139/2004.

2

---